Comparing the current results to its competitors, Sonoma Pharmaceuticals Inc reported Revenue increase in the 3 quarter 2025 by 22.03 % year on year. The sales growth was above Sonoma Pharmaceuticals Inc 's competitors' average revenue growth of 15.29 %, achieved in the same quarter.
Sonoma Pharmaceuticals Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 36.52 %
Sonoma Pharmaceuticals Inc 's Comment on Competition and Industry Peers
The company operates in markets including dermatology, wound care, eye care, podiatry, animal health care, and surface disinfectants. Its hypochlorous acid (HOCl)-based wound and acute care solutions compete with topical anti-infectives, antibiotics, and advanced wound technologies such as skin substitutes, growth factors, and delayed-release silver-based dressings. The company states that its HOCl-based solutions are among the most stable therapeutics available, while some competitors' small molecule HOCl formulations may be unstable or have variable effectiveness. Competitors in these markets possess advantages such as greater name recognition, established relationships with healthcare professionals, patients, and third-party payors, established distribution networks, additional product lines with rebate or bundling capabilities, experience in research and development, manufacturing, regulatory approval, marketing, and greater financial and human resources for product development, sales, marketing, and patient support.
Publicly Traded Peers of Sonoma Pharmaceuticals Inc
Abbvie Inc Share Performance
+13.05%
This Year
Abbvie Inc
Profile
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
Evolus Inc is a pharmaceutical company that operates in the field of aesthetics, with a primary focus on developing and commercializing minimally invasive treatments for patients. Their business model revolves around researching and developing innovative neurotoxin products to address various facial aesthetic concerns. The company aims to bring their products to market through strategic partnerships with healthcare professionals and providers, ensuring widespread accessibility and utilization.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Sources:
Sonoma Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sonoma Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
